- Home
- LEGN
as 09-17-2025 4:00pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.7B | IPO Year: | 2020 |
| Target Price: | $73.36 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.34 - $52.15 | Next Earning Date: | 11-11-2025 |
| Revenue: | $796,838,000 | Revenue Growth: | 74.75% |
| Revenue Growth (this year): | 70.75% | Revenue Growth (next year): | 52.47% |
Latest Legend Biotech Corporation News
LEGN Breaking Stock News: Dive into LEGN Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
RBC Capital Lifts PT on Legend Biotech Corporation (LEGN) to $77 From $75
South China Morning Post
a month ago
China's rise in biotech to potentially lower healthcare costs, life science investor says
MT Newswires
3 months ago
Legend Biotech Valuation Presents 'Buying Opportunity,' RBC Analysts Say
Simply Wall St.
3 months ago
Exploring Three High Growth Tech Stocks in the US Market
Simply Wall St.
3 months ago
High Growth Tech Stocks in US for June 2025
Investor's Business Daily
3 months ago
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
MT Newswires
3 months ago
Legend Biotech Reports 5-Year Survival Data for Carvykti in Multiple Myeloma
GlobeNewswire
3 months ago
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
Compare LEGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.